Elsevier

The Lancet Neurology

Volume 8, Issue 12, December 2009, Pages 1150-1157
The Lancet Neurology

Review
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria

https://doi.org/10.1016/S1474-4422(09)70238-8Get rights and content

Summary

To date, there have been few systematic attempts to provide a standard operating procedure for the neuropathological diagnosis of Parkinson's disease (PD). Pathological examination cannot classify the clinical syndrome with certainty; therefore, the neuropathological diagnosis is, at best, a probability statement. The neuropathological diagnosis of parkinsonism has become increasingly based on fundamental molecular underpinnings, with recognition that the genetics of parkinsonism is heterogeneous and includes disorders that are associated with and without Lewy bodies. The advent of α-synuclein immunohistochemistry has substantially improved the ability to identify Lewy pathology, particularly cortical Lewy bodies and smaller aggregates within processes and the neuropil. In this Review we discuss the diagnostic criteria for the neuropathological assessment of PD. These criteria are provisional and need to be validated through an iterative process that could help with their refinement. Additionally, we suggest future directions for neuropathology research on PD.

Introduction

In contrast to other major neurodegenerative disorders there have been few attempts to provide a standard operating procedure for the neuropathological diagnosis of Parkinson's disease (PD). In this Review, we discuss methodological, molecular, and genetic considerations in making a neuropathological diagnosis of PD that could help in developing guidelines for tissue assessment and could provide a framework to refine standardisation of the neuropathological diagnosis of this disorder.

By focusing on the pathological substrate of clinical parkinsonian syndromes, morphological descriptions are limited to the currently available techniques; furthermore, any observation at postmortem examination is often an imperfect fit with the clinical syndrome. In most cases, attribution of particular clinical features to a given pathological finding is not possible. Consequently, modern neuropathological diagnostic criteria frame diagnosis as a description of the findings and suggest a probabilistic statement about the likelihood that those findings are associated with a particular clinical syndrome.1, 2 This approach is adopted and the prevalence of mixed pathologies considered because a comprehensive assessment of concomitant pathologies is necessary, as has been described for degenerative dementias.3

Section snippets

Molecular classification of parkinsonian disorders

Most available evidence suggests that the neurobiological substrate of the extrapyramidal motor features of parkinsonian disorders is due to nigrostriatal dopaminergic degeneration.4 The morphological correlate of this degeneration is neuronal loss in the pars compacta of the substantia nigra (SNpc), particularly in the ventrolateral tier of neurons in this area.5 When moderate to severe neuronal loss is found in the SNpc, this pathology is usually associated with clinical features consistent

Neuropathological criteria for PD diagnosis

The most common parkinsonian syndrome is sporadic PD. In this disorder, the essential neuropathology is moderate to severe neuronal loss in the SNpc associated with Lewy pathology;46, 47 however, there has never been a formal standard operating procedure or validation for the routine assessment of neuronal loss, even though morphometric assessment of this loss has been confirmed in PD by several groups.48, 49 Neuronal loss in PD most often predominantly affects the ventrolateral area of the

Future directions

The recommended criteria are provisional and need to be validated. Ideally, validation studies would be based on the determination of the reliability, sensitivity, and specificity of the neuropathological diagnostic criteria by a group of neuropathologists65, 66 or by prospective evaluation of patients at postmortem examination, with clinical observations close to the time of death. Such examinations of the neuropathological and genetic basis of PD are likely to provide greater understanding of

Conclusions

Standardisation of the neuropathological diagnostic criteria for PD is the first step in the process of increasing the reliability and validity of its diagnosis. Neuropathological validation studies to refine these criteria and proposed suggestions for neuropathology research will help us further understand what causes the pathogenesis of PD, which we hope will improve the biological therapeutic interventions that can slow or stop disease progression.

Search strategy and selection criteria

References for this Review were identified through searches of PubMed with the search terms “neuropathological diagnosis”, “Parkinson's disease”, “neuropathologic”, “neuropathology”, “criteria”, “autopsy”, and “Parkinson” up to July, 2009. The criteria were based on diagnostic principles of the Parkinson's Disease Society Brain Bank criteria and the Gellb criteria. Additional references were identified from major neuropathology textbooks.

References (93)

  • Y Tsuboi et al.

    Dementia with Lewy bodies and Parkinson's disease with dementia: are they different?

    Parkinsonism Relat Disord

    (2005)
  • Y Tsuboi et al.

    Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology

    Parkinsonism Relat Disord

    (2007)
  • Y Chu et al.

    Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions

    Neurobiol Dis

    (2009)
  • PL McGeer et al.

    The alpha-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease

    Exp Neurol

    (2008)
  • MR Cookson et al.

    Cell systems and the toxic mechanism(s) of alpha-synuclein

    Exp Neurol

    (2008)
  • CF Orr et al.

    An inflammatory review of Parkinson's disease

    Prog Neurobiol

    (2002)
  • BT Hyman et al.

    Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease

    J Neuropathol Exp Neurol

    (1997)
  • IG McKeith et al.

    Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

    Neurology

    (2005)
  • J Lowe

    Establishing a pathological diagnosis in degenerative dementias

    Brain Pathol

    (1998)
  • O Hornykiewicz

    Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness

    Neurodegener Dis

    (2008)
  • JM Fearnley et al.

    Ageing and Parkinson's disease: substantia nigra regional selectivity

    Brain

    (1991)
  • S Greffard et al.

    Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra

    Arch Neurol

    (2006)
  • IR Mackenzie et al.

    Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations

    Acta Neuropathol

    (2009)
  • MJ Farrer et al.

    DCTN1 mutations in Perry syndrome

    Nat Genet

    (2009)
  • M Farrer et al.

    Lewy bodies and parkinsonism in families with parkin mutations

    Ann Neurol

    (2001)
  • PP Pramstaller et al.

    Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers

    Ann Neurol

    (2005)
  • T Gasser

    Update on the genetics of Parkinson's disease

    Mov Disord

    (2007)
  • GG Kovacs et al.

    Mixed brain pathologies in dementia: the BrainNet Europe consortium experience

    Dement Geriatr Cogn Disord

    (2008)
  • KA Jellinger et al.

    Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease

    Acta Neuropathol

    (2008)
  • T Ishizawa et al.

    Colocalization of tau and alpha-synuclein epitopes in Lewy bodies

    J Neuropathol Exp Neurol

    (2003)
  • H Nakashima-Yasuda et al.

    Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases

    Acta Neuropathol

    (2007)
  • Y Yamamura et al.

    Autosomal recessive early-onset parkinsonism with diurnal fluctuation: clinicopathologic characteristics and molecular genetic identification

    Brain Dev

    (2000)
  • H Mori et al.

    Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q

    Neurology

    (1998)
  • MG Spillantini et al.

    Alpha-synuclein in Lewy bodies

    Nature

    (1997)
  • MC Irizarry et al.

    Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity

    J Neuropathol Exp Neurol

    (1998)
  • Y Saito et al.

    Accumulation of phosphorylated alpha-synuclein in aging human brain

    J Neuropathol Exp Neurol

    (2003)
  • S Arawaka et al.

    Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein

    Neurology

    (1998)
  • I Alafuzoff et al.

    Assessment of alpha-synuclein pathology: a study of the BrainNet Europe Consortium

    J Neuropathol Exp Neurol

    (2008)
  • TG Beach et al.

    Evaluation of alpha-synuclein immunohistochemical methods used by invited experts

    Acta Neuropathol

    (2008)
  • E Croisier et al.

    Comparative study of commercially available anti-alpha-synuclein antibodies

    Neuropathol Appl Neurobiol

    (2006)
  • PH Tu et al.

    Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein

    Ann Neurol

    (1998)
  • Y Fumimura et al.

    Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in Lewy body disease

    J Neuropathol Exp Neurol

    (2007)
  • M Ikemura et al.

    Lewy body pathology involves cutaneous nerves

    J Neuropathol Exp Neurol

    (2008)
  • S Orimo et al.

    Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease

    Brain

    (2008)
  • H Braak et al.

    Neuroanatomy and pathology of sporadic Parkinson's disease

    Adv Anat Embryol Cell Biol

    (2009)
  • A Bloch et al.

    Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects

    Neuropathol Appl Neurobiol

    (2006)
  • Cited by (0)

    View full text